Latest filings (excl ownership)
EFFECT
Notice of effectiveness
25 Apr 24
ARS
2023 FY
Annual report to shareholders
22 Apr 24
DEFA14A
Additional proxy soliciting materials
22 Apr 24
DEF 14A
Definitive proxy
22 Apr 24
S-3
Shelf registration
27 Mar 24
S-8
Registration of securities for employees
27 Mar 24
10-K
2023 FY
Annual report
26 Mar 24
8-K
Results of Operations and Financial Condition
26 Mar 24
8-K
Corporate Presentation March 2024 1
19 Mar 24
8-K
Departure of Directors or Certain Officers
1 Feb 24
8-K
Corporate Presentation January 2024 1
12 Jan 24
8-K
Regulation FD Disclosure
8 Jan 24
8-K
Corporate Presentation December 2023 1
4 Dec 23
8-K
Corporate Presentation November 2023 1
13 Nov 23
10-Q
2023 Q3
Quarterly report
13 Nov 23
8-K
Acumen Pharmaceuticals Reports Third Quarter 2023 Financial Results and Business Highlights
13 Nov 23
8-K
Entry into a Material Definitive Agreement
8 Nov 23
10-Q
2023 Q2
Quarterly report
8 Aug 23
8-K
Acumen Pharmaceuticals Reports Second Quarter 2023 Financial Results and Business Highlights
8 Aug 23
424B5
Prospectus supplement for primary offering
20 Jul 23
8-K
Entry into a Material Definitive Agreement
20 Jul 23
424B5
Prospectus supplement for primary offering
17 Jul 23
8-K
Results of Operations and Financial Condition
17 Jul 23
8-K
Acumen Pharmaceuticals Presents Positive Topline Results from First-in-Human
17 Jul 23
8-K
Amendments to Articles of Incorporation or Bylaws
8 Jun 23
10-Q
2023 Q1
Quarterly report
9 May 23
8-K
Acumen Pharmaceuticals Reports First Quarter 2023 Financial Results and Business Highlights
9 May 23
DEFA14A
Additional proxy soliciting materials
27 Apr 23
ARS
2022 FY
Annual report to shareholders
27 Apr 23
DEF 14A
Definitive proxy
27 Apr 23
424B5
Prospectus supplement for primary offering
27 Apr 23
8-K
Entry into a Material Definitive Agreement
27 Apr 23
PRE 14A
Preliminary proxy
14 Apr 23
S-8
Registration of securities for employees
28 Mar 23
10-K
2022 FY
Annual report
27 Mar 23
8-K
Acumen Pharmaceuticals Reports Financial Results for Recent Business Highlights and Anticipated Milestones
27 Mar 23
8-K
Amendments to Articles of Incorporation or Bylaws
15 Mar 23
8-K
Regulation FD Disclosure
1 Feb 23
8-K
Departure of Directors or Certain Officers
4 Jan 23
10-Q
2022 Q3
Quarterly report
14 Nov 22
Latest ownership filings
SC 13G/A
Deep Track Capital, LP
14 Feb 24
SC 13G
FRANKLIN RESOURCES INC
6 Feb 24
4
James J. Doherty
1 Feb 24
3
James J. Doherty
1 Feb 24
SC 13G/A
MURRAY JAMES B JR
24 Jan 24
4
Daniel Joseph OConnell
19 Jan 24
4
Derek M Meisner
19 Jan 24
4
Matt Zuga
19 Jan 24
4
Eric Siemers
19 Jan 24
4
Russell Barton
19 Jan 24
144
Notice of proposed sale of securities
19 Jan 24
144
Notice of proposed sale of securities
19 Jan 24
144
Notice of proposed sale of securities
18 Jan 24
144
Notice of proposed sale of securities
18 Jan 24
144
Notice of proposed sale of securities
18 Jan 24
4
Russell Barton
4 Jan 24
4
Derek M Meisner
4 Jan 24
4
Eric Siemers
4 Jan 24
4
Matt Zuga
4 Jan 24
4
Daniel Joseph OConnell
4 Jan 24
4
Jeffrey L. Ives
18 Aug 23
144
Notice of proposed sale of securities
17 Aug 23
SC 13D/A
RA CAPITAL MANAGEMENT, L.P.
25 Jul 23
4
Peter Kolchinsky
25 Jul 23
4
Peter Kolchinsky
13 Jun 23
4
John A Stalfort III
7 Jun 23
4
Laura Stoppel
7 Jun 23
4
Derrell Porter
7 Jun 23
4
Jeffrey L. Ives
7 Jun 23
4
Nathan B Fountain
7 Jun 23
4
Kimberlee C Drapkin
7 Jun 23
SC 13G/A
Manning Paul B
14 Feb 23
SC 13G/A
Sands Capital Ventures, LLC
14 Feb 23
SC 13G/A
Deep Track Capital, LP
14 Feb 23
4
Matt Zuga
18 Jan 23
4
Eric Siemers
18 Jan 23
4
Daniel Joseph OConnell
18 Jan 23
4
Derek M Meisner
18 Jan 23
4
Russell Barton
18 Jan 23
4
Derrell Porter
4 Jan 23